Literature DB >> 33623607

Psychiatric side effects of chloroquine in COVID-19 patients: two case reports.

Roukaya Benjelloun1, Yassine Otheman2, Chafik El Kettani1.   

Abstract

Chloroquine and hydroxy chloroquine are widely use in Africa and all over the world as anti-malarial drugs but also in the treatment of chronic inflammatory diseases. Since the outbreak of COVID-19 pandemic, Morocco have included this medication in the COVID-19 treatment guidelines in association with azithromycine. Besides dermatologic problems, ocular impairments and gastro-intestinal effects, quinolines may also cause rarely described psychiatric adverse effects. To our knowledge, there has been no reports of psychiatric side effects of chloroquine or hydroxy chloroquine in the actual context of COVID-19 pandemic. Here, we present the description of two COVID-19 patients who showed psychiatric side effects after chloroquine treatment. One patient expressed psychotic symptoms and the other one experienced acute and intense anxiety. In both cases, and according to Naranjo score, the association between chloroquine and psychiatric side effects was probable. © Roukaya Benjelloun et al.

Entities:  

Keywords:  COVID-19; Chloroquine; anxiety; hallucination; psychiatry; side effect

Year:  2020        PMID: 33623607      PMCID: PMC7875809          DOI: 10.11604/pamj.supp.2020.35.24064

Source DB:  PubMed          Journal:  Pan Afr Med J


  16 in total

Review 1.  Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology.

Authors:  Piyush Das; Abhishek Rai; Amit Chopra; Kemuel Philbrick
Journal:  Psychosomatics       Date:  2013-11-21       Impact factor: 2.386

2.  Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection.

Authors:  Denise S Telgt; Andre J van der Ven; Barbara Schimmer; Han A Droogleever-Fortuyn; Robert W Sauerwein
Journal:  Ann Pharmacother       Date:  2005-03       Impact factor: 3.154

Review 3.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Toxic psychosis due to chloroquine--not uncommon in children.

Authors:  P Garg; P Mody; K B Lall
Journal:  Clin Pediatr (Phila)       Date:  1990-08       Impact factor: 1.168

6.  Chloroquine-induced recurrent psychosis.

Authors:  Saddichha Sahoo; Manoj Kumar; Vinod K Sinha
Journal:  Am J Ther       Date:  2007 Jul-Aug       Impact factor: 2.688

7.  Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report.

Authors:  Tuan M Tran; Joseph Browning; Mary L Dell
Journal:  Malar J       Date:  2006-08-23       Impact factor: 2.979

8.  Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity.

Authors:  Jan Kehr; Takashi Yoshitake; Fumio Ichinose; Shimako Yoshitake; Béla Kiss; István Gyertyán; Nika Adham
Journal:  Psychopharmacology (Berl)       Date:  2018-04-11       Impact factor: 4.530

9.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Authors:  Christian A Devaux; Jean-Marc Rolain; Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-12       Impact factor: 5.283

10.  No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.

Authors:  J M Molina; C Delaugerre; J Le Goff; B Mela-Lima; D Ponscarme; L Goldwirt; N de Castro
Journal:  Med Mal Infect       Date:  2020-03-30       Impact factor: 2.152

View more
  4 in total

1.  New-Onset Mania and Psychosis in Adolescents in the Context of COVID-19 Infection.

Authors:  Ryan Meeder; Samicchya Adhikari; Kiela Sierra-Cintron; Kapil Aedma
Journal:  Cureus       Date:  2022-04-20

Review 2.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 3.  Safety profile of COVID-19 drugs in a real clinical setting.

Authors:  Mei Nee Chiu; Maitry Bhardwaj; Sangeeta Pilkhwal Sah
Journal:  Eur J Clin Pharmacol       Date:  2022-01-28       Impact factor: 3.064

4.  Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect?

Authors:  David A Forero-Peña; Matthew M Hernandez; Iriana Paola Mozo Herrera; Iván Bolívar Collado Espinal; Joselyn Páez Paz; Carlos Ferro; David M Flora-Noda; Andrea L Maricuto; Viledy L Velásquez; Natasha A Camejo-Avila; Emilia M Sordillo; Lourdes A Delgado-Noguera; Luis A Perez-Garcia; Carlos G Morantes Rodríguez; María Eugenia Landaeta; Alberto E Paniz-Mondolfi
Journal:  J Med Virol       Date:  2021-11-19       Impact factor: 20.693

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.